Targeted News Service

Breztri Approved in the U.S. for Asthma as First and Only Triple Therapy for Patients 12 Years of Age and Older
April 29, 2026

WILMINGTON, Delaware, April 29 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older

Approval based on KALOS and LOGOS Phase III trials demonstrating statistically

significant and clinically meaningful benefits of AstraZeneca's single-inhaler fixed-dose triple therapy compared with inhaled dual thera . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form